Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc)

• Published in: International journal of impotence research 2018-10, Vol.30 (5), p.209-214
• Main Authors: Yafi, Faysal A., Tallman, Christopher T., Seard, Melvin L., Jordan, Mark L.
• Format: Article
• Language: English
• Subjects: 692/698/1864/1752; 692/699/2768/515; Ablation Techniques - adverse effects; Ablation Techniques - methods; Aged; Aged, 80 and over; Cohort Studies; Humans; Hyperplasia; Lower Urinary Tract Symptoms - etiology; Lower Urinary Tract Symptoms - surgery; Male; Medicine; Medicine & Public Health; Mens health; Middle Aged; Prospective Studies; Prostate; Prostate - pathology; Prostate - surgery; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - pathology; Prostatic Hyperplasia - surgery; Reproductive Medicine; Robotic Surgical Procedures - adverse effects; Robotic Surgical Procedures - methods; rology; Treatment Outcome; United States; Urology; Water
• ISSN: 0955-9930; 1476-5489
• DOI: 10.1038/s41443-018-0045-3

Between September and December 2017, 82 men with moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia LUTS/BPH and prostate volume of 80–150 cc underwent Aquablation in a prospective multicenter clinical trial in the United States. Baseline patient and clinical demographics and standardized postoperative parameters were collected and tabulated in a central independently monitored database. Adverse events through 3 months were adjudicated by an independent clinical events committee. Mean pre-treatment prostate volume was 108 ± 21.1 cc. Mean operative time was 38.2 ± 14.4 min and mean Aquablation resection time was 7.7 ± 3.3 min. Additional electrocautery for hemostasis was not needed in any patient following Aquablation. The average length of stay following the procedure was 1.6 ± 1.0 days. Mean pre- and 3 months post-treatment IPSS scores were 23.7 ± 6.4 and 7.1 ± 5.1, –16.6, p